Faeth Therapeutics, Inc.

FTH

Faeth Therapeutics, Inc.

FTH

Insider Sentiment (TTM):

Last Purchase:2026-06-26Last Sale:2026-06-01Shares Purchased (TTM):35,102Shares Sold (TTM):102,898

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:2,459,500Shares Outstanding:1,295,052Institutional Ownership Pct.:189.92%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	27	152	9	11	13	10	10	19	12	11	13	11
Available For Sale Securities Debt Securities Curr…	160	50	13	14	16	24	31	28	40	47	53	61
Prepaid Expense Current	1	1	0	0	1	1	0	1	2	2	1	2
Other Assets Current	1	0	0	0	0	0	0	0	0	0	0	0
Assets Current	189	204	22	26	30	36	42	48	54	60	67	74
Operating Lease Right Of Use Asset	1	1	1	2	2	2	3	3	4	4	4	5
Finance Lease Right Of Use Asset	-	0	0	0	0	0	0	1	1	1	2	2
Property Plant And Equipment Net	0	0	0	0	0	0	0	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	189	205	23	28	32	38	45	53	60	67	74	82
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	8	9	1	1	1	2	1	2	2	2	2	3
Employee Related Liabilities Current	1	4	1	1	1	1	2	1	1	1	2	1
Operating Lease Liability Current	1	1	1	2	2	2	2	2	2	2	2	2
Finance Lease Liability Current	-	0	0	0	0	1	1	1	1	1	1	1
Liabilities Current	10	14	4	4	4	5	5	5	5	5	6	6
Operating Lease Liability Noncurrent	0	0	0	0	1	1	1	2	2	3	3	3
Finance Lease Liability Noncurrent	-	-	0	0	0	0	0	0	0	1	1	1
Other Liabilities Noncurrent	0	0	-	-	-	-	-	-	0	0	0	0
Liabilities	10	14	4	5	4	6	7	7	8	8	9	11
Redeemable Noncontrolling Interest Equity Preferre…	7	328	-	-	-	-	-	-	-	-	-	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	642	316	302	301	301	301	300	300	299	298	297	296
Retained Earnings Accumulated Deficit	-469	-453	-283	-278	-274	-269	-262	-254	-247	-240	-232	-224
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	-0	-0	-0	-0	0	-0	-0	-0	-0
Stockholders Equity	173	-137	19	23	27	32	38	46	52	58	65	71
Liabilities And Stockholders Equity	189	205	23	28	32	38	45	53	60	67	74	82
Series B Redeemable Convertible Preferred Stock	-	0	-	-	-	-	-	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	-	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	-	-	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	-	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	13	13	13	250	250	13	250	250	250	250	250
Common Stock Shares Issued	26	1	1	1	1	1	1	1	1	1	1	1
Shares Outstanding	26	1	1	1	1	1	1	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-31.06%	-	-	-	-	-	-	-	-	-	-	-
2025	-24.13%	9.21%	-12.18%	1.40%	6.80%	28.16%	21.42%	20.49%	18.68%	26.50%	-29.21%	-
2024	-52.89%	-60.50%	-57.91%	-6.80%	-14.54%	-13.86%	-0.24%	9.28%	1.71%	-20.22%	-32.32%	-40.98%
2023	-	-	-	-	-	-	-1.57%	-1.28%	14.12%	37.65%	14.12%	80.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	19.69	14.39	5.06	5.81	7.64	6.82	7.70	8.84	10.90	12.07	11.92	11.86
Quick Ratio	19.55	14.32	5.00	5.70	7.42	6.65	7.61	8.65	10.59	11.69	11.71	11.62
Working Capital	179.08M	190.04M	17.26M	21.35M	25.70M	30.45M	36.48M	42.66M	49.00M	55.24M	61.61M	67.61M
Leverage & Debt
Debt to Equity	0.06	-0.10	0.23	0.20	0.16	0.20	0.18	0.16	0.15	0.14	0.15	0.15
Interest Coverage TTM	-22,091.11	-9,770.58	-696.50	-556.63	-468.48	-415.44	-362.38	-312.33	-279.28	-267.58	-257.39	-131.57
Debt Ratio	0.05	0.07	0.19	0.17	0.14	0.16	0.15	0.14	0.13	0.12	0.13	0.13
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-34.65	-142.43	-16.72	-19.14	-21.27	-23.05	-24.01	-23.70	-23.64	-25.48	-24.40	-30.51
Free Cash Flow Per Share TTM	-5.36	-18.62	-16.24	-12.13	-13.63	-19.26	-19.76	-20.03	-19.42	-22.33	-23.04	-27.92
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	628.96%	535.42%	-30.08%	-19.00%	-9.60%	-9.05%	-11.57%	-23.43%	-34.37%	-31.16%	-29.82%	-14.88%
EPS Growth (1Y)	62.87%	517.99%	-30.36%	-19.26%	-10.01%	-9.56%	-1.58%	-22.31%	-20.24%	-15.17%	-22.91%	2.49%
Valuation Metrics
P/E TTM	-0.72	-0.22	-0.64	-0.49	-0.40	-0.34	-0.41	-0.50	-0.52	-0.82	-0.57	-0.52
P/B TTM	0.82	-0.30	0.72	0.52	0.40	0.31	0.32	0.33	0.30	0.45	0.30	0.29
Market Cap	141.08M	40.82M	13.45M	11.92M	10.82M	9.93M	12.31M	15.04M	15.56M	26.30M	19.34M	20.41M
Enterprise Value	114.18M	-111.49M	4.86M	1.55M	-1.39M	666.10K	3.14M	-3.06M	4.91M	16.79M	7.97M	10.90M
Calculated Values
Free Cash Flow TTM	-30.23M	-24.11M	-20.47M	-15.30M	-17.19M	-24.26M	-24.82M	-25.19M	-24.38M	-27.97M	-32.20M	-35.61M
Net Debt	-26.90M	-152.31M	-8.59M	-10.37M	-12.21M	-9.26M	-9.16M	-18.09M	-10.65M	-9.51M	-11.37M	-9.51M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Purchase

Owner: Stephenson, Brian C

Title: Chief Financial Officer

Shares: 6,250

Price/Share: $25.11

Value: $156,937.50

Shares Owned: 33,054

Relationship: Officer

Ownership: Indirect

2026-06-23Purchase

Owner: Stephenson, Brian C

Title: Chief Financial Officer

Shares: 9,230

Price/Share: $24.96

Value: $230,380.80

Shares Owned: 17,413

Relationship: Officer

Ownership: Indirect

2026-06-22Purchase

Owner: Parikh, Anand Kiran

Title: President and CEO

Shares: 2,806

Price/Share: $19.76

Value: $55,446.56

Shares Owned: 764,234

Relationship: Director,Officer

Ownership: Direct

2026-06-01Sale

Owner: Cambrian, Biopharma Inc

Title: -

Shares: 25,000

Price/Share: $20.57

Value: $514,250.00

Shares Owned: 130,142

Relationship: TenPercentOwner

Ownership: Direct

2026-06-01Sale

Owner: Peyer, James

Title: -

Shares: 25,000

Price/Share: $20.57

Value: $514,250.00

Shares Owned: 130,142

Relationship: TenPercentOwner,Other

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Stephenson, Brian C	Officer	Chief Financial Officer	Indirect	Purchase	6,250	25.11	$156,937.50	33,054	4
2026-06-23	Stephenson, Brian C	Officer	Chief Financial Officer	Indirect	Purchase	9,230	24.96	$230,380.80	17,413	4
2026-06-22	Parikh, Anand Kiran	Director,Officer	President and CEO	Direct	Purchase	2,806	19.76	$55,446.56	764,234	4
2026-06-01	Cambrian, Biopharma Inc	TenPercentOwner	-	Direct	Sale	25,000	20.57	$514,250.00	130,142	4
2026-06-01	Peyer, James	TenPercentOwner,Other	-	Direct	Sale	25,000	20.57	$514,250.00	130,142	4
2026-04-07	Ics, Opportunities Ii Llc…	TenPercentOwner	-	Indirect	Sale	8,151	31.13	$253,740.63	133,986	4
2026-04-07	Ics, Opportunities Ii Llc…	TenPercentOwner	-	Indirect	Purchase	1,108	33.38	$36,985.04	133,986	4
2026-04-01	Millennium, Management Ll…	TenPercentOwner	-	Indirect	Sale	1,150	33.14	$38,111.00	147,731	4
2026-04-01	Millennium, Management Ll…	TenPercentOwner	-	Indirect	Purchase	6,175	33.86	$209,085.50	147,731	4
2026-03-30	Ics, Opportunities Ii Llc…	TenPercentOwner	-	Indirect	Purchase	9,533	26.36	$251,289.88	145,678	4
2026-03-30	Ics, Opportunities Ii Llc…	TenPercentOwner	-	Indirect	Sale	888	26.76	$23,762.88	145,678	4
2025-12-09	Peyer, James	TenPercentOwner,Other	-	Indirect	Sale	3,507	7.97	$27,950.79	155,142	4
2025-12-09	Cambrian, Biopharma Inc	TenPercentOwner	-	Direct	Sale	6,612	8.12	$53,689.44	155,142	4
2025-12-05	Peyer, James	TenPercentOwner,Other	-	Indirect	Sale	16,295	12.28	$200,102.60	161,359	4
2025-12-05	Cambrian, Biopharma Inc	TenPercentOwner	-	Direct	Sale	16,295	12.28	$200,102.60	161,359	4
2023-09-11	Celebi, John	Director,Officer	President and CEO	Direct	Purchase	500	0.85	$425.00	111,311	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

189.92%

Inst. Shares: 2,459,500

Shares Outstanding: 1,295,052

2025-12-31

3.83%

Inst. Shares: 48,240

Shares Outstanding: 1,260,772

2025-09-30

3.91%

Inst. Shares: 49,335

Shares Outstanding: 1,261,290

2025-06-30

5.55%

Inst. Shares: 69,928

Shares Outstanding: 1,260,867

2025-03-31

151.68%

Inst. Shares: 1,910,395

Shares Outstanding: 1,259,531

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	2,459,500	1,295,052	189.92%
2025-12-31	48,240	1,260,772	3.83%
2025-09-30	49,335	1,261,290	3.91%
2025-06-30	69,928	1,260,867	5.55%
2025-03-31	1,910,395	1,259,531	151.68%
2024-12-31	2,336,026	1,255,776	186.02%
2024-09-30	2,206,817	1,257,299	175.52%
2024-06-30	2,103,677	1,255,145	167.60%
2024-03-31	2,094,694	25,049,111	8.36%
2023-12-31	2,700,304	27,952,857	9.66%
2023-09-30	2,921,749	25,514,115	11.45%
2023-06-30	2,950,838	30,507,018	9.67%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Faeth Therapeutics, Inc. (FTH) — SEC Financial Statements & Analysis

Faeth Therapeutics, Inc. (FTH) is a pharmaceutical preparations company, incorporated in DE. Faeth Therapeutics, Inc. trades on Nasdaq as: FTH. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Faeth Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.06x, a Price-to-Book (P/B) ratio of 0.82x (TTM), at a market cap of $141.08M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.06x
P/B TTM: 0.82x
Market Cap: $141.08M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Faeth Therapeutics, Inc. in?

Faeth Therapeutics, Inc. (FTH) operates in the Pharmaceutical Preparations industry.

What is FTH's market cap?

Faeth Therapeutics, Inc. (FTH) has a market capitalization of $141.08M as of 2026-06-30.

What exchange does FTH trade on?

Faeth Therapeutics, Inc. (FTH) trades on the Nasdaq.

Where is Faeth Therapeutics, Inc. incorporated?

Faeth Therapeutics, Inc. is incorporated in DE.